News and Press Releases

Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease

Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4 VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025

Route de la Corniche 8 1066 Epalinges Switzerland

NHS patients receive medicines manufactured by Octapharma using UK-donated plasma for the first time in almost 30 years 

The sole manufacturer for the UK’s Plasma for Medicines (PfM) programme is supporting the Department of Health and Social Care, NHS England, and NHS Blood and Transplant to build resilience...

Category: Other, Pharmaceutical
Posted: March 6, 2025

Glassworks House 32 Shudehill Manchester M4 1EZ

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. 4 March 2025 -- Texas, US -- FibroBiologics, Inc, a clinical-stage biotechnology...

Category: Biotechnology, Other, Pharmaceutical
Posted: March 4, 2025

455 E. Medical Center Blvd. Suite 300 Houston, TX 77598